在一项涉及广泛期 SCLC 患者的 3 期试验的预设中期分析中，采用 #Tarlatamab 维持治疗的中位总生存期为 21.1 个月，单用 durvalumab 则为 12.7 个月。
#ESMO26
https://www.nejm.org/doi/full/10.1056/NEJMoa2609482?referrer=https%3A%2F%2Ft.co%2F
495 浏览 · 3 赞 · 2 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：C. Michael Gibson MD · x.com